期刊文献+

巨细胞病毒感染对射频消融术后心房颤动复发的影响

Influence of cytomegalovirus infection on recurrence of atrial fibrillation after radiofrequency catheter ablation
原文传递
导出
摘要 目的:探讨巨细胞病毒(CMV)感染对射频消融术后心房颤动(房颤)复发的预测价值。方法 :严格筛选103例首次接受射频消融治疗的孤立性房颤患者,随访观察患者射频消融术后房颤复发情况。所有患者于射频消融术前检测血清CMV免疫球蛋白(Ig)G抗体水平。结果:平均随访(12.8±7.0)个月,29例患者房颤复发。与未复发者相比,复发者年龄较小[(54.03±9.84)比(59.1±11.0)岁,P=0.034]、血清CMV Ig G抗体水平较高[(260.24±29.10)比(241.34±33.49)mg/L,P=0.01]。Cox多元回归分析显示,血清CMV Ig G抗体水平是消融术后房颤复发的独立危险因素[风险比(HR)=1.013,95%可信区间(CI):1.0~1.025,P=0.029]。血清CMV Ig G抗体水平截断值为237.61μg/m L时预测房颤复发的灵敏度为83%,特异度为49%。结论:CMV感染与射频消融术后房颤复发相关,房颤患者的血清CMV Ig G抗体水平预测消融术后房颤复发具有良好的敏感性。 Objective To analyze the influence of cytomegalovirus(CMV) infection on recurrence of atrial fibrillation(AF) after successful radiofrequency catheter ablation(RFCA). Methods One hundred and three lone AF patients initially undergoing RFCA were enrolled and evaluated. Level of immunoglobulin G(Ig G) antibody against CMV was monitored before RFCA. Results During a mean follow-up period of(12.8 ±7.0) months, 29 patients had recurrence of AF. AF patients with recurrence were younger [(54.03±9.84) vs(59.1±11.0) years, P=0.034], and had a significantly higher level of anti-CMV Ig G than patients without AF recurrence [(260.24 ±29.10) vs(241.34 ±33.49) mg/L, P =0.01]. Cox multivariate regression analysis revealed that anti-CMV Ig G level was an independent risk factor of AF recurrence[hazard ratio(HR)=1.013, 95% confidence interval(CI) 1.0-1.025, P=0.029]. Cut-off point of 237.61 μg/m L for antiCMV Ig G had a sensitivity of 83% and specificity of 49% in predicting AF recurrence. Conclusions CMV infection is associated with the recurrence of AF after radiofrequency catheter ablation. Level of anti-CMV Ig G is sensitive for the prediction of post-RFCA AF recurrence.
出处 《内科理论与实践》 2016年第1期15-19,共5页 Journal of Internal Medicine Concepts & Practice
基金 国家国际科技合作专项项目(项目编号:2013DFB30310) 北京市医院管理局重点医学专业发展计划(项目编号:ZYLX201302) 国家科技支撑计划课题(项目编号:2013BAI09B02)
关键词 心房颤动 巨细胞病毒感染 导管射频消融术 复发 Atrial fibrillation Cytomegalovirus infection Radiofrequency catheter ablation Recurrence
  • 相关文献

参考文献32

  • 1January CT, Wann IS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol, 2014, 64(21): E1-E76.
  • 2Friedrichs K, Baldus S, Klinke A. Fibrosis in atrial fibrillation - role of reactive species and MPO [J]. Front Physiol, 2012, 3: 214.
  • 3Krogh-Madsen T, Abbott GW, Christini DJ. Effects of electrical and structural remodeling on atrial fibrillation maintenance: a simulation study [J]. PLoS Comput Biol, 2012, 8(2): E1002390.
  • 4Zhao F, Zhang S, Chen L, et al. Calcium- and integrin- binding protein-1 and calcineurin are upregulated in the right atrial myocardium of patients with atrial fibrillation [J]. Europace, 2012, 14(12): 1726-1733.
  • 5Chiang CH, Huang CC, Chan WL, et al. Herpes simplex virus infection and risk of atrial fibrillation: a nationwide study[J]. Int J Cardiol, 2013, 164(2): 201-204.
  • 6Wang DZ, Chen W, Yang S, et al. Helicobacter pylori infection in Chinese patients with atrial fibrillation [J]. Clin Interv Aging, 2015, 10: 813-819.
  • 7Mahfoud F, Goirtner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility?[J]. Eur Heart J, 2011, 32(7): 897-903.
  • 8Ueda Y, Kenzaka T, Noda A, et al. Adult-onset Kawasaki disease (mucoeutaneous lymph node syndrome) and concurrent Coxsaekievirus A4 infection: a ease report[J]. Int Med Case Rep J, 2015, 8: 225-230.
  • 9马长生,刘少伟.心力衰竭合并心房颤动的治疗策略进展[J].内科理论与实践,2014,9(1):11-15. 被引量:23
  • 10Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review[J]. Heart Rhythm, 2010, 7(6): 835-846.

二级参考文献30

  • 1Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study [J]. Circulation, 2003, 107(23): 2920-2925.
  • 2Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implica- tions for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study[J]. JAMA, 2001, 285(18): 2370-2375.
  • 3Smit MD, Moes ML, Maass AH, et al. The importance of whether atrial fibrillation or heart failure develops first [J]. Eur J Heart Fail, 2012, 14(9): 1030-1040.
  • 4Suzuki S, Sagara K, Otsuka T, et al. A new scoring sys- tem for evaluating the risk of heart failure events in Japanese patients with atrial fibrillation [J]. Am J Cardiol, 2012, 110(5): 678-682.
  • 5Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation [J]. N Engl J Med, 2010, 362(15): 1363-1373.
  • 6Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation [J]. JACC Heart Fail, 2013, 1(1): 21-28.
  • 7Wbitbeek MG, Chamigo R J, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study [J]. Eur Heart J, 2013, 34(20): 1481- 1488.
  • 8Van Veldhuisen D J, Van Gelder IC, Ahmed A, et al. Digoxin for patients with atrial fibrillation and heart fail- ure: paradise lost or not? [J]. Eur Heart J, 2013, 34(20): 1468-1470.
  • 9Cohn JN. Inotropic therapy for heart failure: paradise lost [J]. Eur Heart J, 2009, 30(24): 2965-2966.
  • 10Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial [J]. N Engl J Med, 1991, 324(12): 781-788.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部